摘要
目的通过免疫组化检测原发性肝癌中嘧啶核苷磷酸化酶(PyNPase)的表达,揭示依赖于嘧啶核苷磷酸化酶转化的化疗药物在临床应用的分子基础。方法从我院外科2001年6月至2004年6月间183例原发性肝癌手术切除标本中随机抽取40例作为实验组。术前均未经任何放化疗。并随机抽取同期肝内胆管结石手术肝切除标本40例,且证实为正常肝组织,作为对照组。使用SP免疫组化法分别检测肝癌细胞与正常肝细胞PyNPase的表达。结果原发性肝癌细胞和正常肝细胞PyNPase的表达指数分别为62.34+/-19.53和12.61+/-10.17,有显著性差异(P<0.05)。不同组织分型的肝癌组织的PyNPase的表达也有显著的差异(P<0.05)。结论原发性肝癌细胞中PyNPase呈高表达,则提示其对依赖于嘧啶核苷磷酸化酶转化的化疗药物如氟铁龙,希罗达等更为敏感。
Objective To explore the expression of Pyrimidine Nucleoside Phosphorylase(PyNPase) in hepatocellular carcinoma and reveal molicular bio-basis about the chemotheraputic drugs converted by PyNPase.Methods From Jun 2001 to Jun 2004,in 183 cases underwent hepatectomy for hepatocellular carcinoma,40 specimens were randomly selected as the experimental group. At the same time, 40 cases of normal liver tissue specimens were selected as control group. Immunohistochemical staining had been used to detect the expression of PyNPase in both groups. Results The expressions of PyNPase between HCC(62.34+/-19.53) and normal liver cells(12.61+/-10.17)were significantly difference(P < 0.05). The expression of PyNPase in different HCC Edmondson classification also showed significant difference(P < 0.05). Conclusion The HCC high expressed PyNPase showed it would be the sensitivity to Furtulon or Xeloda.
出处
《岭南现代临床外科》
2005年第1期69-70,共2页
Lingnan Modern Clinics in Surgery
